Search research articles
Contact Us
Filters
Showing results (1-10 of 7) with videos related to
Page
of 1
Sort By:
Trials
|
June 6, 2020
Cluster randomised trials of prescribing policy: an ethical approach to generating drug safety evidence? A discussion of the ethical application of a new research method
Amy Rogers, Gillian Craig, Angela Flynn, et al.
British Journal of Clinical Pharmacology
|
March 10, 2017
Electronic case report forms and electronic data capture within clinical trials and pharmacoepidemiology
David A Rorie, Robert W V Flynn, Kerr Grieve, et al.
BMJ Open
|
June 1, 2022
Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study
Amy Rogers, Evelien Rooke, Steve Morant, et al.
Antioxidants (Basel, Switzerland)
|
August 26, 2022
The Prognostic Value of Derivatives-Reactive Oxygen Metabolites (d-ROMs) for Cardiovascular Disease Events and Mortality: A Review
Filippo Pigazzani, Davide Gorni, Kenneth A Dyar, et al.
Lancet (London, England)
|
September 29, 2015
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Bryan Williams, Thomas M MacDonald, Steve Morant, et al.
Pharmacoepidemiology and Drug Safety
|
January 2, 2021
Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis
Daniel R Morales, Tatiana Macfarlane, Thomas M MacDonald, et al.
Research Involvement and Engagement
|
July 7, 2026
Embedding the public voice in clinical trials: developing public-informed training for patient data research
Fiona V Lugg-Widger, Caroline Brocklehurst, Sarah Chave, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 7) with videos related to
Sort By:
Page
of 1
Trials
|
June 6, 2020
Cluster randomised trials of prescribing policy: an ethical approach to generating drug safety evidence? A discussion of the ethical application of a new research method
Amy Rogers, Gillian Craig, Angela Flynn, et al.
British Journal of Clinical Pharmacology
|
March 10, 2017
Electronic case report forms and electronic data capture within clinical trials and pharmacoepidemiology
David A Rorie, Robert W V Flynn, Kerr Grieve, et al.
BMJ Open
|
June 1, 2022
Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study
Amy Rogers, Evelien Rooke, Steve Morant, et al.
Antioxidants (Basel, Switzerland)
|
August 26, 2022
The Prognostic Value of Derivatives-Reactive Oxygen Metabolites (d-ROMs) for Cardiovascular Disease Events and Mortality: A Review
Filippo Pigazzani, Davide Gorni, Kenneth A Dyar, et al.
Lancet (London, England)
|
September 29, 2015
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Bryan Williams, Thomas M MacDonald, Steve Morant, et al.
Pharmacoepidemiology and Drug Safety
|
January 2, 2021
Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis
Daniel R Morales, Tatiana Macfarlane, Thomas M MacDonald, et al.
Research Involvement and Engagement
|
July 7, 2026
Embedding the public voice in clinical trials: developing public-informed training for patient data research
Fiona V Lugg-Widger, Caroline Brocklehurst, Sarah Chave, et al.
Page
of 1